Innate Pharma SA
PAR:IPH

Watchlist Manager
Innate Pharma SA Logo
Innate Pharma SA
PAR:IPH
Watchlist
Price: 1.946 EUR 1.14%
Market Cap: 157.5m EUR
Have any thoughts about
Innate Pharma SA?
Write Note

Operating Margin
Innate Pharma SA

-155.3%
Current
-117%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-155.3%
=
Operating Profit
-38.6m
/
Revenue
24.9m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
FR
Innate Pharma SA
PAR:IPH
160.9m EUR
-155%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
310.3B USD
28%
US
Amgen Inc
NASDAQ:AMGN
141.6B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
134.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
35.8B EUR
-22%
Country FR
Market Cap 160.9m EUR
Operating Margin
-155%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 310.3B USD
Operating Margin
28%
Country US
Market Cap 141.6B USD
Operating Margin
19%
Country US
Market Cap 115.3B USD
Operating Margin
38%
Country US
Market Cap 102.4B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 134.4B AUD
Operating Margin
26%
Country US
Market Cap 77.3B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 35.8B EUR
Operating Margin
-22%
No Stocks Found

Innate Pharma SA
Glance View

Market Cap
157.5m EUR
Industry
Biotechnology

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. The company is headquartered in Marseille, Paca and currently employs 215 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The firm works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.

IPH Intrinsic Value
5.098 EUR
Undervaluation 62%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-155.3%
=
Operating Profit
-38.6m
/
Revenue
24.9m
What is the Operating Margin of Innate Pharma SA?

Based on Innate Pharma SA's most recent financial statements, the company has Operating Margin of -155.3%.